ImClone Officials Ordered Shredders. By Justin Gillis. September 14, 2002. Samuel and Harlan Waksal, the two brothers who ran ImClone Systems Inc., ordered shredders ...

ImClone Systems Inc.'s high-water mark was a sweet deal last fall in which its shareholders were allowed to sell a portion of their holdings to drug giant Bristol-Myers Squibb Co. for $70 a share.

Biotechnology company ImClone Systems Inc. said Wednesday that it is considering a buyout offer worth $70 per share from an unidentified large pharmaceutical company and rejected a $60-per-share ...

Imclone Systems biopharmaceutical manufacturing facility in Branchburg was approved by the FDA in July 2002, according to pharmaceutical-technology.com. BRANCHBURG - A manufacturing operation at ...

BOSTON (CBS.MW) -- ImClone Systems announced Monday that it had filed its delayed annual report with regulators, a significant step toward regaining compliance with Nasdaq listing requirements ...

NEW YORK — ImClone Systems’ board of directors said Monday cancer-drug partner Bristol-Myers Squibb’s $4.5 billion buyout offer “substantially undervalues” the company, with Chairman ...

Sam Waksal, the founder of ImClone Systems who fell from grace before the company became $6.5 billion takeover property for Eli Lilly, is back in the biotech world, trying to raise $50 million for ...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction Creates a Global Leader in Oncology Biopharmaceuticals Boosts Oncology Pipeline With Up to Three Promising Targeted Therapies in ...

WASHINGTON (CBS.MW) -- Former ImClone Systems chief executive Sam Waksal declined to testify before House lawmakers Thursday about his company's failed application for its colon cancer drug ...

Among the mysteries surrounding the implosion of ImClone Systems Inc. is the terrible timing of a $1.2-billion investment in the company by Bristol-Myers Squibb Co. The pharmaceutical giant ...

Shares of ImClone Systems Inc. dropped nearly 18% Monday on worries that the launch of the company's crucial colorectal-cancer drug, Erbitux, may be delayed longer than expected. The setback also ...